Treatment of Chronic Infections

Treatment provided by the Immunotherapy Department

1. It is possible to treat Hepatitis B · Hepatitis C?
2. The treatment period is about half a year
3. There are no serious side effects
4. Treatment is also possible in asymptomatic stages

Chronic Infectious Diseases Such as Hepatitis B and Hepatitis C

Chronic Liver Disease Caused by Hepatitis
As causes of chronic liver disease in Japan, about 70% of Hepatitis C and about 15% of Hepatitis B are combined, and the viral Hepatic disease accounts for nearly 90%. The number of people with persistent infection (carrier) of Hepatitis B virus (HBV virus) in Japan is about 1.3 to 1.5 million, of which about 15% is said to have chronic liver disease. The number of Hepatitis C virus (HCV virus) carriers is about 1.5 million to 2 million of which about 50% has chronic liver disease.

Removal of the Hepatitis B and Hepatitis C Virus Dramatically Reduces Liver Cancer Mortality
Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are extremely dangerous as they can cause hepatocellular carcinoma and indeed 95% of Japanese hepatocellular carcinoma carriers are currently infected with Hepatitis B and Hepatitis C. It is caused by a virus. Furthermore, liver cancer is very likely to recur. It is assumed that about 80% of cases in radical therapy (local therapy and post resection) relapse within 5 years. Therefore, if Hepatitis B virus and Hepatitis C virus can be removed prophylactically before the onset of liver cancer, it is thought that the number of patients who die of liver cancer will decrease sharply.

Exploration of Safer Treatment
In recent years, insurance for interferon, lamivudine (Zephix), adefovir pivoxil (Hepsella), entecavir, hydrate (ballaclude) is available for chronic Hepatitis B. Interferon and ribazerin can also be billed to health insurance for chronic Hepatitis C. Advances in drug therapy are very pleasing, but adaptation is limited, and considering the side effects of each drug, the emergence of resistant viruses, relapse and exacerbation after discontinuation of treatment, etc., treatment is desirable.

Treatment Flow

First Consulation

• Examination and inquiries
• Examination of medical condition and present condition so far.
• Blood test
• Echo examination (Hepatitis only)

Second Consultation

• I will explain the future “treatment plan” based on the results of the initial examination.
  In case of doubts and uncertainties, please do not hesitate to ask about the treatment plan. If you agree, sign the approval form.

Start of Treatment

• Prescription for internal medicine
• Administration of visiting GcMAF and high-concentration vitamin C once a week (1 course 8 times / about 2 months)

Regular Medical Examination and Medications
I regularly receive consultation and confirm the medical condition.

Research Papers

A research paper related to therapy “macrophage activation therapy” that activates sleeping immune cells.

Stability of GcMAF Serum (English / PDF)

A paper demonstrating that human serum containing GcMAF can be used as a potential macrophage activator in cancer immunotherapy (English / PDF)

Clinical experience of integrated cancer immunotherapy with GcMAF (English / PDF)

Treatment Cost

Click here for further information.